News

pluripotency

Find us here ...

Subscribe to our newsletter

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.

No spam - just the good stuff

More

News

pluripotency

BlueRock’s cell therapy shows early promise in Parkinson’s study

Finding the recipe for success in cell therapy

New regenerative stem cell therapy for heart disease shows promise

Tapping the potential of mRNA in cellular reprogramming and beyond

A new approach to accurately predict cellular reprogramming cocktails

“Immortal jellyfish” could unlock aging clues

Stem cells, longevity and the final frontier

Exploring the relationship between partial reprogramming and epigenetic rejuvenation

Genflow Biosciences moves into cellular reprogramming

Find us here ...

Subscribe to our newsletter

More